MDisrupt, a consulting venture launched this week, is aiming to help digital health startups and their potential investors avoid another Theranos-like disaster, CNBC reports.
The firm, helmed by 23andMe alum Ruby Gadelrab and Jill Hagenkord, MD, who has served as chief medical officer for both 23andMe and biotech startup Color Genomics, is billed as "the world's first medical diligence company for the health tech industry." MDisrupt will work with investors to bridge the gap between the Silicon Valley adage of "move fast and break things" and medicine's core tenet to "first do no harm."
To do so, the company will help investors determine whether early-stage health tech companies' products and services are based on valid scientific claims, if they are following proper regulatory procedures, how they are ensuring health data privacy and whether the business plan is solid, the founders told CNBC.
"We are hoping to help the good startups move faster and get recognition for their work while we also root out the bad ones," Ms. Gadelrab told the outlet.
More articles on health IT:
WebMD acquires point-of-care decision-making platform
MD Anderson, Boehringer launch virtual center for data-driven drug discovery
Former Lehigh Valley patient claims physician inappropriately accessed his medical records